Canada’s Prof Michael Butler named incoming NIBRT CSO

22 Mar 201639 Shares

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Nibrt complex image via NIBRT

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

The National Institute for Bioprocessing Research and Training (NIBRT) in Dublin has announced its new chief scientific officer (CSO) will be Prof Michael Butler, who will take up the role on 1 September.

NIBRT is one of Ireland’s largest research and training centres in Ireland in the fields of bioprocessing, and it recently moved to a new facility built to closely replicate a modern bioprocessing plant with all of the advanced equipment that comes with that.

Now, it has been announced that it has turned to Canada to recruit one of the world’s leading experts on mammalian cell culture bioprocessing, who will join the research and training organisation as its new CSO.

Butler will relocate to NIBRT from Canada where he is currently serving as a Distinguished Professor of Animal Cell Technology at the University of Manitoba, and is also the Scientific Director of the Canadian Monoclonal Antibody Network (MabNet).

Throughout his research career, he has led the development of mammalian cell culture bioprocesses for scale-up and industrial production.

Leading NIBRT’s research programme

He is also the author of seven books, and more than 100 peer-reviewed scientific articles with a strong record of leading industry-academic collaborations and he will now lead NIBRT’s research programme focused on biopharmaceutical manufacturing research.

Commenting on his appointment, Butler said: “I’m delighted to be able to move to NIBRT and be a part of the impressive growth that’s taking place in the country’s biopharmaceutical industry.

“I especially look forward to partnering with the academic and industry research communities as we collaborate on addressing the key scientific challenges in biopharma manufacturing research”.

Adding to this sentiment, NIBRT’s CEO Dominic Carolan said: “Mike’s knowledge, expertise in mammalian cell culture, and international reputation is an ideal fit for NIBRT’s research strategy and is a great addition to our well-established research team.”

66

DAYS

4

HOURS

26

MINUTES

Buy your tickets now!

Colm Gorey is a journalist with Siliconrepublic.com

editorial@siliconrepublic.com